NTRB vs PRGO vs HLN vs DARE

For growth investors, Perrigo Company plc (PRGO) is the stronger pick with -2.

8% revenue growth year-over-year, versus -99. 7% for Daré Bioscience, Inc. (DARE). Haleon plc (HLN) offers the better valuation at 19. 0x trailing P/E (22. 2x forward), making it the more compelling value choice. Analysts rate Haleon plc (HLN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Perrigo Company plc is actually cheaper at 5.

6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Haleon plc (HLN) delivered a total return of +31.

7%, compared to -82. 4% for Daré Bioscience, Inc. (DARE). Over 10 years, the gap is even starker: HLN returned +31. 7% versus DARE's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Haleon plc (HLN) is the lower-risk stock at 0.

06β versus Nutriband Inc. 's 1. 20β — meaning NTRB is approximately 1870% more volatile than HLN relative to the S&P 500. On balance sheet safety, Nutriband Inc. (NTRB) carries a lower debt/equity ratio of 3% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Perrigo Company plc (PRGO) is pulling ahead at -2.

8% versus -99. 7% for Daré Bioscience, Inc. (DARE). On earnings-per-share growth, the picture is similar: Daré Bioscience, Inc. grew EPS 88. 4% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, HLN leads at -0. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Haleon plc (HLN) is the more profitable company, earning 15.

1% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HLN leads at 22. 4% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — HLN leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 22. 2x for Haleon plc — 16. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

In this comparison, PRGO (9.

8% yield), HLN (1. 9% yield) pay a dividend. NTRB, DARE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Haleon plc (HLN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 1. 9% yield). Both have compounded well over 10 years (HLN: +31. 7%, NTRB: -34. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NTRB is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; HLN is a mid-cap quality compounder stock; DARE is a small-cap quality compounder stock. PRGO, HLN pay a dividend while NTRB, DARE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.